177 related articles for article (PubMed ID: 38519031)
1. Dual-specificity kinase DYRK3 phosphorylates p62 at the Thr-269 residue and promotes melanoma progression.
Lee YH; Yoon AR; Yun CO; Chung KC
J Biol Chem; 2024 Apr; 300(4):107206. PubMed ID: 38519031
[TBL] [Abstract][Full Text] [Related]
2. DYRK3 phosphorylates SNAPIN to regulate axonal retrograde transport and neurotransmitter release.
Lee YH; Suh BK; Lee U; Ryu SH; Shin SR; Chang S; Park SK; Chung KC
Cell Death Discov; 2022 Dec; 8(1):503. PubMed ID: 36585413
[TBL] [Abstract][Full Text] [Related]
3. Dual Specificity Kinase DYRK3 Promotes Aggressiveness of Glioblastoma by Altering Mitochondrial Morphology and Function.
Kim K; Lee S; Kang H; Shin E; Kim HY; Youn H; Youn B
Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33804169
[TBL] [Abstract][Full Text] [Related]
4. DYRK1A and DYRK3 promote cell survival through phosphorylation and activation of SIRT1.
Guo X; Williams JG; Schug TT; Li X
J Biol Chem; 2010 Apr; 285(17):13223-32. PubMed ID: 20167603
[TBL] [Abstract][Full Text] [Related]
5. Dual specificity kinase DYRK3 couples stress granule condensation/dissolution to mTORC1 signaling.
Wippich F; Bodenmiller B; Trajkovska MG; Wanka S; Aebersold R; Pelkmans L
Cell; 2013 Feb; 152(4):791-805. PubMed ID: 23415227
[TBL] [Abstract][Full Text] [Related]
6. Dual-Specificity Tyrosine Phosphorylation-Regulated Kinase 3 Loss Activates Purine Metabolism and Promotes Hepatocellular Carcinoma Progression.
Ma F; Zhu Y; Liu X; Zhou Q; Hong X; Qu C; Feng X; Zhang Y; Ding Q; Zhao J; Hou J; Zhong M; Zhuo H; Zhong L; Ye Z; Xie W; Liu Y; Xiong Y; Chen H; Piao D; Sun B; Gao Z; Li Q; Zhang Z; Qiu X; Zhang Z
Hepatology; 2019 Nov; 70(5):1785-1803. PubMed ID: 31066068
[TBL] [Abstract][Full Text] [Related]
7. PAICS/DYRK3 Multienzyme Interactions as Coregulators of Purinosome Formation and Metabolism on Radioresistance in Oral Squamous Cell Carcinoma.
Huang CS; Hsieh MS; Yadav VK; Wu YC; Liu SC; Yeh CT; Huang MS
Int J Mol Sci; 2023 Dec; 24(24):. PubMed ID: 38139175
[TBL] [Abstract][Full Text] [Related]
8. Hsp90-mediated regulation of DYRK3 couples stress granule disassembly and growth via mTORC1 signaling.
Mediani L; Antoniani F; Galli V; Vinet J; Carrà AD; Bigi I; Tripathy V; Tiago T; Cimino M; Leo G; Amen T; Kaganovich D; Cereda C; Pansarasa O; Mandrioli J; Tripathi P; Troost D; Aronica E; Buchner J; Goswami A; Sterneckert J; Alberti S; Carra S
EMBO Rep; 2021 May; 22(5):e51740. PubMed ID: 33738926
[TBL] [Abstract][Full Text] [Related]
9. DYRK3 activation, engagement of protein kinase A/cAMP response element-binding protein, and modulation of progenitor cell survival.
Li K; Zhao S; Karur V; Wojchowski DM
J Biol Chem; 2002 Dec; 277(49):47052-60. PubMed ID: 12356771
[TBL] [Abstract][Full Text] [Related]
10. Intestinal cell kinase (ICK) promotes activation of mTOR complex 1 (mTORC1) through phosphorylation of Raptor Thr-908.
Wu D; Chapman JR; Wang L; Harris TE; Shabanowitz J; Hunt DF; Fu Z
J Biol Chem; 2012 Apr; 287(15):12510-9. PubMed ID: 22356909
[TBL] [Abstract][Full Text] [Related]
11. mTOR-mediated Na
Yang Y; Luo Z; Hao Y; Ba W; Wang R; Wang W; Ding X; Li C
Biomed Pharmacother; 2017 Aug; 92():744-749. PubMed ID: 28591687
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of mTOR kinase by AZD8055 can antagonize chemotherapy-induced cell death through autophagy induction and down-regulation of p62/sequestosome 1.
Huang S; Yang ZJ; Yu C; Sinicrope FA
J Biol Chem; 2011 Nov; 286(46):40002-12. PubMed ID: 21949121
[TBL] [Abstract][Full Text] [Related]
13. Focal Adhesion- and IGF1R-Dependent Survival and Migratory Pathways Mediate Tumor Resistance to mTORC1/2 Inhibition.
Yoon SO; Shin S; Karreth FA; Buel GR; Jedrychowski MP; Plas DR; Dedhar S; Gygi SP; Roux PP; Dephoure N; Blenis J
Mol Cell; 2017 Aug; 67(3):512-527.e4. PubMed ID: 28757207
[TBL] [Abstract][Full Text] [Related]
14. MCM7 silencing promotes cutaneous melanoma cell autophagy and apoptosis by inactivating the AKT1/mTOR signaling pathway.
Yang Y; Ma S; Ye Z; Zhou X
J Cell Biochem; 2020 Feb; 121(2):1283-1294. PubMed ID: 31535400
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of mTORC1 by SU6656, the selective Src kinase inhibitor, is not accompanied by activation of Akt/PKB signalling in melanoma cells.
Ondrušová L; Réda J; Záková P; Tuháčková Z
Folia Biol (Praha); 2013; 59(4):162-7. PubMed ID: 24093774
[TBL] [Abstract][Full Text] [Related]
16. Dyrk kinases regulate phosphorylation of doublecortin, cytoskeletal organization, and neuronal morphology.
Slepak TI; Salay LD; Lemmon VP; Bixby JL
Cytoskeleton (Hoboken); 2012 Jul; 69(7):514-27. PubMed ID: 22359282
[TBL] [Abstract][Full Text] [Related]
17. mTOR complex 2 (mTORC2) controls hydrophobic motif phosphorylation and activation of serum- and glucocorticoid-induced protein kinase 1 (SGK1).
García-Martínez JM; Alessi DR
Biochem J; 2008 Dec; 416(3):375-85. PubMed ID: 18925875
[TBL] [Abstract][Full Text] [Related]
18. Small molecule H89 renders the phosphorylation of S6K1 and AKT resistant to mTOR inhibitors.
Melick CH; Jewell JL
Biochem J; 2020 May; 477(10):1847-1863. PubMed ID: 32347294
[TBL] [Abstract][Full Text] [Related]
19. mTORC1 signaling can regulate growth factor activation of p44/42 mitogen-activated protein kinases through protein phosphatase 2A.
Harwood FC; Shu L; Houghton PJ
J Biol Chem; 2008 Feb; 283(5):2575-85. PubMed ID: 18056704
[TBL] [Abstract][Full Text] [Related]
20. Epigallocatechin-3-gallate(EGCG) suppresses melanoma cell growth and metastasis by targeting TRAF6 activity.
Zhang J; Lei Z; Huang Z; Zhang X; Zhou Y; Luo Z; Zeng W; Su J; Peng C; Chen X
Oncotarget; 2016 Nov; 7(48):79557-79571. PubMed ID: 27791197
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
